Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report

Tai Zhao; Yajin Wang; Yuqing Du

doi:doi:10.11648/j.crj.20221002.11

| Peer-Reviewed

Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report

Tai Zhao, Yajin Wang, Yuqing Du

Published in Cancer Research Journal (Volume 10, Issue 2)

Received: 15 February 2022 Accepted: 15 March 2022 Published: 14 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an effective means of leiomyosarcoma, while radiotherapy is mainly aimed at subclinical lesions and residual lesions. There is no standard treatment for advanced retroperitoneal leiomyosarcoma. How to effectively prolong the survival time of patients is worth discussing. Aim: To determine the comprehensive treatment of retroperitoneal leiomyosarcoma based on surgery, and to explore the effective prolongation of the survival time of patients with advanced retroperitoneal leiomyosarcoma. Case Summary: A female with pelvic leiomyosarcoma survived for 70 months after surgery, postoperative radiotherapy, local ablation and chemoembolization. Finally, multiple metastases of lung and liver occurred, abdominal distension and fatigue was hospitalized. After oral administration of anlotinib 12mg q1-14d, she survived for 10 months. Conclusion: Leiomyosarcoma needs multidisciplinary comprehensive treatment based on surgery. Late-line anti angiogenesis therapy with arotinib can improve the quality of life of patients and effectively prolong the progression free survival of advanced patients because of its mild adverse reactions, good tolerance and Oral convenience.

Published in	Cancer Research Journal (Volume 10, Issue 2)
DOI	10.11648/j.crj.20221002.11
Page(s)	26-29
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Leiomyosarcoma, Surgery, Radiotherapy, Anlotinib Hydrochloride, Case Report

References

[1]	Wang Guanhuier, He Lianbo, Yang Kaiwei, et al. (2016). Primary retroperitoneal leiomyosarcoma: a clinical and pathological study of 11 cases. Chinese Journal of Urology, 37 (12): 916-918.
[2]	Ramponi F, Kench JG, Simring DV, et al. (2012). Early diagnosis and resection of an asymptomatic leiomvosarcoma of the inferior vena cava prior to caval obstruction. J Vasc Surg, 55: 525-528.
[3]	Chouliaras K, Senehi R, Ethun CG, et al (2019). Recurrence patterns after resection of retroperitoneal sarcomas: an eight-institution study from the US Sarcoma Collaborative, J. Surg. Oncol. 120: 340–347.
[4]	Snow HA, Hitchen TX, Head J, et al (2018). Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre, ANZ J. Surg. 88: 1151–1157.
[5]	Nao Kitasakia, Tomoyuki Abea, Akihiko Oshita, et al (2021). Long-term survival by repeat resection for metastases from primaryretroperitoneal leiomyosarcoma: A case report. International Journal of Surgery Case Reports 82: 105891.
[6]	ZHAO Xudong, LI Peiyu, HUANG Xiaohui, et al. (2013). Prognostic factors predicting postoperative survival period in the treatment of primary retroperitoneal leiomyosarcoma. Chinese Journal of Surgery, 51 (10): 891-893.
[7]	Constantinidou A, Jones RL (2018). Systemic therapy in retroperitoneal sarcomamanagement, J. Surg. Oncol. 117: 87–92.
[8]	WANG Fuming, LIU Jingyu, YANG Jijin (2018). Drug-eluting beads for the treatment of hepatic metastasis following surgery of retroperitioneal leiomyosarcoma: report of one case. Journal of Interventional Radiology, 27 (4): 308-309.
[9]	Yoo KH, Kim HS, Lee SJ, et al. (2015). Emcacy of pazopanib monotherapy in patients who had been heavily pretrealed for metastatic soft tissue sarcoma:a retrospective case series. BMc cancer, 15: 154-166.
[10]	CHI Y, FANG Z, HONG X, et al (2018). Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res, 24 (21): 5233-5238.
[11]	ZHUANG Rong-yuan, WANG Zhi-ming, GUO Xi, et al (2019). The short-term efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma. Chinese Journal of Clinical Medicine, 26: 378-381.
[12]	Jiayong Liu, Zhengfu Fan, Shu Li (2018). Anlotinib hydrochloride capsules for advanced soft tissue sarcoma: single-center data analysis of a stage II multicenter clinical trial. Chinese Journal of Clinical Oncology, 45 (20): 1066-1070.
[13]	Sun Y, Niu W, Du F, Du C, et al (2016). Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol, 9 (1): 105-106.
[14]	LIN Li, KONG Fei, ZHANG Guifen, et al (2019). Clinical Efficacy and Safbty of Anlotillib in me TreatInent of Advanced Soft Tissue Sarcoma. JOURNAL 0F BASIC AND CLINICAL 0NCOLOGY, 32 (3): 223-225.

Cite This Article

Plain Text BibTeX RIS

APA Style

Tai Zhao, Yajin Wang, Yuqing Du. (2022). Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report. Cancer Research Journal, 10(2), 26-29. https://doi.org/10.11648/j.crj.20221002.11

Copy | Download

ACS Style

Tai Zhao; Yajin Wang; Yuqing Du. Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report. Cancer Res. J. 2022, 10(2), 26-29. doi: 10.11648/j.crj.20221002.11

Copy | Download

AMA Style

Tai Zhao, Yajin Wang, Yuqing Du. Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report. Cancer Res J. 2022;10(2):26-29. doi: 10.11648/j.crj.20221002.11

Copy | Download

@article{10.11648/j.crj.20221002.11,
  author = {Tai Zhao and Yajin Wang and Yuqing Du},
  title = {Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report},
  journal = {Cancer Research Journal},
  volume = {10},
  number = {2},
  pages = {26-29},
  doi = {10.11648/j.crj.20221002.11},
  url = {https://doi.org/10.11648/j.crj.20221002.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221002.11},
  abstract = {Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an effective means of leiomyosarcoma, while radiotherapy is mainly aimed at subclinical lesions and residual lesions. There is no standard treatment for advanced retroperitoneal leiomyosarcoma. How to effectively prolong the survival time of patients is worth discussing. Aim: To determine the comprehensive treatment of retroperitoneal leiomyosarcoma based on surgery, and to explore the effective prolongation of the survival time of patients with advanced retroperitoneal leiomyosarcoma. Case Summary: A female with pelvic leiomyosarcoma survived for 70 months after surgery, postoperative radiotherapy, local ablation and chemoembolization. Finally, multiple metastases of lung and liver occurred, abdominal distension and fatigue was hospitalized. After oral administration of anlotinib 12mg q1-14d, she survived for 10 months. Conclusion: Leiomyosarcoma needs multidisciplinary comprehensive treatment based on surgery. Late-line anti angiogenesis therapy with arotinib can improve the quality of life of patients and effectively prolong the progression free survival of advanced patients because of its mild adverse reactions, good tolerance and Oral convenience.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report
AU  - Tai Zhao
AU  - Yajin Wang
AU  - Yuqing Du
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.crj.20221002.11
DO  - 10.11648/j.crj.20221002.11
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 26
EP  - 29
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20221002.11
AB  - Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an effective means of leiomyosarcoma, while radiotherapy is mainly aimed at subclinical lesions and residual lesions. There is no standard treatment for advanced retroperitoneal leiomyosarcoma. How to effectively prolong the survival time of patients is worth discussing. Aim: To determine the comprehensive treatment of retroperitoneal leiomyosarcoma based on surgery, and to explore the effective prolongation of the survival time of patients with advanced retroperitoneal leiomyosarcoma. Case Summary: A female with pelvic leiomyosarcoma survived for 70 months after surgery, postoperative radiotherapy, local ablation and chemoembolization. Finally, multiple metastases of lung and liver occurred, abdominal distension and fatigue was hospitalized. After oral administration of anlotinib 12mg q1-14d, she survived for 10 months. Conclusion: Leiomyosarcoma needs multidisciplinary comprehensive treatment based on surgery. Late-line anti angiogenesis therapy with arotinib can improve the quality of life of patients and effectively prolong the progression free survival of advanced patients because of its mild adverse reactions, good tolerance and Oral convenience.
VL  - 10
IS  - 2
ER  -

Copy | Download

Author Information

Tai Zhao

Department of Interventional Radiology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China
Yajin Wang

Department of Interventional Radiology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China
Yuqing Du

Department of Interventional Radiology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Tai Zhao, Yajin Wang, Yuqing Du. (2022). Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report. Cancer Research Journal, 10(2), 26-29. https://doi.org/10.11648/j.crj.20221002.11

Copy | Download

ACS Style

Tai Zhao; Yajin Wang; Yuqing Du. Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report. Cancer Res. J. 2022, 10(2), 26-29. doi: 10.11648/j.crj.20221002.11

Copy | Download

AMA Style

Tai Zhao, Yajin Wang, Yuqing Du. Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report. Cancer Res J. 2022;10(2):26-29. doi: 10.11648/j.crj.20221002.11

Copy | Download

@article{10.11648/j.crj.20221002.11,
  author = {Tai Zhao and Yajin Wang and Yuqing Du},
  title = {Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report},
  journal = {Cancer Research Journal},
  volume = {10},
  number = {2},
  pages = {26-29},
  doi = {10.11648/j.crj.20221002.11},
  url = {https://doi.org/10.11648/j.crj.20221002.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221002.11},
  abstract = {Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an effective means of leiomyosarcoma, while radiotherapy is mainly aimed at subclinical lesions and residual lesions. There is no standard treatment for advanced retroperitoneal leiomyosarcoma. How to effectively prolong the survival time of patients is worth discussing. Aim: To determine the comprehensive treatment of retroperitoneal leiomyosarcoma based on surgery, and to explore the effective prolongation of the survival time of patients with advanced retroperitoneal leiomyosarcoma. Case Summary: A female with pelvic leiomyosarcoma survived for 70 months after surgery, postoperative radiotherapy, local ablation and chemoembolization. Finally, multiple metastases of lung and liver occurred, abdominal distension and fatigue was hospitalized. After oral administration of anlotinib 12mg q1-14d, she survived for 10 months. Conclusion: Leiomyosarcoma needs multidisciplinary comprehensive treatment based on surgery. Late-line anti angiogenesis therapy with arotinib can improve the quality of life of patients and effectively prolong the progression free survival of advanced patients because of its mild adverse reactions, good tolerance and Oral convenience.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Analysis of the Efficacy of Anlotinib in the Late-Line Treatment of Advanced Leiomyosarcoma: A Case Report
AU  - Tai Zhao
AU  - Yajin Wang
AU  - Yuqing Du
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.crj.20221002.11
DO  - 10.11648/j.crj.20221002.11
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 26
EP  - 29
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20221002.11
AB  - Primary retroperitoneal leiomyosarcoma originated from smooth muscle tissue or mesenchymal cells with the potential to differentiate into smooth muscle cells, showing aggressive growth, easy to recur and metastasize after operation, with a 5-year overall survival rate of 28% - 40%. Multidisciplinary comprehensive treatment based on surgery is an effective means of leiomyosarcoma, while radiotherapy is mainly aimed at subclinical lesions and residual lesions. There is no standard treatment for advanced retroperitoneal leiomyosarcoma. How to effectively prolong the survival time of patients is worth discussing. Aim: To determine the comprehensive treatment of retroperitoneal leiomyosarcoma based on surgery, and to explore the effective prolongation of the survival time of patients with advanced retroperitoneal leiomyosarcoma. Case Summary: A female with pelvic leiomyosarcoma survived for 70 months after surgery, postoperative radiotherapy, local ablation and chemoembolization. Finally, multiple metastases of lung and liver occurred, abdominal distension and fatigue was hospitalized. After oral administration of anlotinib 12mg q1-14d, she survived for 10 months. Conclusion: Leiomyosarcoma needs multidisciplinary comprehensive treatment based on surgery. Late-line anti angiogenesis therapy with arotinib can improve the quality of life of patients and effectively prolong the progression free survival of advanced patients because of its mild adverse reactions, good tolerance and Oral convenience.
VL  - 10
IS  - 2
ER  -

Copy | Download